Uncategorized

MOTS-C is one of the most distinctive peptides in current longevity and metabolic research — not least because of where it comes from. Here is what it is, what it is known for, and what to look for when sourcing it. What is MOTS-C? MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is…

The research story around GLP-1 class peptides is expanding well beyond glycaemic control and weight. Here is a summary of what current studies suggest about GLP-1 activity and biological ageing — positioned strictly within a research and laboratory context. Beyond Metabolic Biology GLP-1 receptor agonists — including semaglutide, tirzepatide, and retatrutide — have been the…

Eli Lilly’s retatrutide has completed multiple Phase 3 trials under the TRIUMPH programme. Here is a summary of what the published data shows, positioned strictly within a research context. Background: What is TRIUMPH? TRIUMPH (Treatment of Obesity with Retatrutide — Investigational Uplift in Metabolic Profile and Health) is the Phase 3 clinical development programme for…

MOTS-C and NAD+ are two of the most-discussed molecules in mitochondrial and longevity research. They are often mentioned in the same conversations because they operate in the same broad biological space — mitochondrial function, energy metabolism, and age-related decline — but they belong to entirely different classes of molecule. MOTS-C is a peptide encoded within the mitochondrial genome; NAD+ is a coenzyme central to redox reactions.

BPC-157 and KPV are two of the most widely referenced peptides in inflammation and gastrointestinal research. They share overlapping research applications — particularly in colitis, wound healing, and mucosal repair models — but they are structurally very different, act through completely different biological pathways, and derive from unrelated parent molecules.

Ipamorelin and Tesamorelin are two of the most-studied peptides in growth-hormone-axis research, and both are frequently referenced in the same conversations. They are often used together in research protocols because they act on entirely different receptors — Ipamorelin at the ghrelin receptor, Tesamorelin at the GHRH receptor.

Semax and Selank are two Russian-developed synthetic heptapeptides that are frequently mentioned together, often studied in parallel, and sometimes assumed to be closely related. They share several structural features — both are seven-amino-acid peptides, both use a Pro-Gly-Pro C-terminal extension for enzymatic stability, and both were registered as medicinal products in Russia — but they derive from entirely different parent molecules and are studied in largely non-overlapping research contexts.

Tirzepatide and Retatrutide are two of the most significant incretin-based peptides developed by Eli Lilly, and both have generated substantial research interest in metabolic and glycaemic biology. They share a common design lineage — Retatrutide was developed after Tirzepatide, extending the same 39-amino-acid GIP-backbone architecture — but differ in one critical way: the number of receptor targets. This comparison walks through the shared design, the receptor differences, current research directions, and how to think about the two compounds side-by-side.

BPC-157 and TB-500 are the two most extensively studied peptides in tissue-repair research. They are often mentioned together, sometimes assumed to be interchangeable, and frequently combined in preclinical studies — but they originate from entirely different biological sources and act through distinct mechanisms. This comparison walks through the origins, chemistry, research applications, and key differences between the two, positioned strictly within a research context.

What Retatrutide is, what it’s known for in metabolic and weight-loss research, why its triple-agonist design stands out, and what to look for when sourcing it.